retatrutide cardiac side effects effects: what the trials show and how to manage them Why some of my patients

Tirzepatide represents the step up when semaglutide results plateau or when insulin resistance is a primary concern given its GIP mechanism

[DOI] [PMC free article] [PubMed] [Google Scholar] 133.Rosenstock J, Wysham C, Fras JP, Kaneko S, Lee CJ, et al

But the full picture is more nuanced than that, and the specific timeline depends heavily on your dose, your titration schedule, and your individual biology

Stay well hydrated to prevent severe dehydration

Visceral adiposity, which leads to insulin resistance, is the putative mechanism in the development of diabesity, leading to insulin dependent Type 2 diabetes.2 The GLP-1 journey did not stop at treating Type 2 diabetes alone but has moved on to treating obesity, typically using higher dosing. THE RISE OF GLP-1 AGONISTS (INCRETIN MIMETICS) Along with newer classes of oral drugs for treating Type 2 diabetes such as DPP-IV (dipeptidyl peptidase-4) inhibitors and SGLT-2 (sodium-glucose co-transporter-2) inhibitors, the GLP-1 (glucagon-like peptide-1) receptor agonist drug class is being prescribed to combat Type 2 diabetes and to slow patient progression towards insulin dependency